Virtual Library
Start Your Search
A. Bruni
Author of
-
+
P2.02 - Poster Session with Presenters Present (ID 462)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Locally Advanced NSCLC
- Presentations: 2
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.02-020 - Pattern of Care of Inoperable Locally Advanced (LA) NSCLC in Elderly Patients: Analysis of the Experience of Two Academic Italian Hospitals (ID 6038)
14:30 - 14:30 | Author(s): A. Bruni
- Abstract
Background:
Optimal treatment in LA NSCLC patients is still debated. In fit patients concomitant radio-chemotherapy (RCT) seems to be the best treatment in terms of local control (LC), progression free survival (PFS) and overall survival (OS) while sequential RCT is a good alternative in unfit patients. Moderately hypofractionated radiotherapy improve OS in recent studies. Elderly patients often cannot be offered multimodality treatments. We report our experience with over 70 years old LA NSCLC patients deemed unfit for surgery.
Methods:
Characteristics of patients and treatments are summarized in table 1. All patients were treated with a platinum based doublet of chemotherapy (CT). RT target volumes included the primary lung tumor and involved mediastinal lymphnodes as defined on pre-treatment contrast enhanced CT scan. Elective nodal irradiation was not performed. Acute/late toxicities were reported in accordance to 4.0 CTCAE scale. Clinical response was evaluated according to RECIST criteria.Patients' Characteristics Age Median 75 Range 70-83 Gender Male 50 (70%) Female 21 (30%) Performance Status (ECOG) 0 29 (41%) 1 36 (51%) 2 6 (8%) Histology Adenocarcinoma 31 (44%) Squamous Cell Carcinoma 39 (55%) Large Cell Carcinoma 1 (1%) Stage IIa/IIb 12 (17%) IIIa 39 (55%) IIIb 20 (28%) Chemotherapy Concomitant 9 (13%) Sequential 62 (87%) Cycles: median 4 Cycles: range 1-8 Radiotherapy Median Dose 62,3 Gy Moderate hypofractionation 26 (37%) Conventional fractionation 45 (63%)
Results:
At a median follow up of 10 months clinical response was evaluable in 69/71 patients obtaining a partial response in 35 of them, stable disease in 17, progressive disease in 17 patients. Twenty six patients experienced a local relapse within RT primary tumor volume, while 13 on nodal volume (5 patients both tumor and nodal relapse). 22 patients developed metastatic disease. One and 3-year OS was 62.3%(SE±6.2%) and 24,5%(SE±7.8%) respectively, while 1- and 3 year PFS was 45.1%(SE±6.9%) and 9,7%(SE±5.7%) respectively. At univariate analysis, tumor dimension (p<0,002) was the only prognostic factor statistically significant for OS. G1-G2 acute toxicity was observed in 45 patients: 36/62 in sequential CRT (3/36 developed also chronic toxicities) and 9/9 in concomitant CRT; most events were G1 oesophagitis (27 patients) and G1 cough (17 patients). No G3-4 event was reported.
Conclusion:
CRT is feasible in elderly patients; multidisciplinary evaluation is needed in order to reserve CRT to very fit patients.
-
+
P2.02-058 - Moderately Hypofractionated Radiotherapy in Locally Advanced Non Small Cell Lung Cancer: A Single Institution Retrospective Analysis (ID 4450)
14:30 - 14:30 | Author(s): A. Bruni
- Abstract
Background:
Radiation dose escalation using hypofractionation might improve clinical outcomes. Aim of the study was to evaluate outcomes, safety and feasibility of a moderately hypofractionated Radiotherapy (Hypo-RT) regimen for pts with LA-NSCLC
Methods:
Between 2008 and 2015 44 consecutive pts with LA-NSCLC were treated using a HYPO-RT regimen.Thirty-two pts were male,12 female. Mean age was 66.2 years. Primary tumor was adenocarcinoma in 16 pts, SCC in 27, Giant Cell neurendocrine Carcinoma in 1 pt.Three pts had clinical stage IIA-IIB, 19 pts IIIA and 22 IIIB. Chemotherapy was administered before Hypo-RT in 37 pts, 7 pts underwent exclusive RT. Mean total RT dose delivered to site of persistent disease was 61 Gy (range 45-66Gy) and mean total treatment time was 40 days in 5,7 weeks(range 3-8) . Daily fraction ranged between 2.2 and 3 Gy. RT was temporarily interrupted in 3 pts due to acute toxicity.
Results:
After a median follow up of 17.3 months, 19 pts were alive, whereas 25 pts had died (18 pts due to disease progression and 7 from other causes). Complete response was achieved in 6 pts, partial response in 16 and stable disease in 10 with an overall response rate (ORR) equal to 72,7%. Twenty-one pts showed locoregional relapse;17 pts distant metastasis and 6 pts both of them. Median overall survival (OS) was 41.7 months while 1,3- and 5-year OS were 68.9%(±7,2%SE), 44.9%(±8.3%SE) and 25.1 (±9.0SE), respectively. At univariate analysis local failure, stage and response to CHT-RT treatment showed a statistically significant impact on OS with better prognosis for pts in stage IIIA, achieving a complete response and not experiencing locoregional relapse ( p< 0.04, <0.05, <0.02 respectively). At the same interval progression free survival was 52.3%(ES±7.8),17.8%(ES±6.6) and 11.9 (ES±6.5) while 3- and 5-years locoregional control was 24.6%(ES±5,5) and 11.7%(ES±4,7%).Acute toxicities were reported in 27 pts: 4 pts had G1-G2 skin dermatitis, 16 pts G1-G2 esophagitis and 4 pts G1-G2 pneumonitis. About late toxicities 7 pts experienced G1-G2 pneumonitis while 3 pts had G1-G2 esophagitis. No deaths related to the treatment were recorded.
Conclusion:
Hypo-RT proved to be a feasible and well tolerated treatment for pts with LA-NSCLC showing very promising results in terms of overall response rate and clinical outcomes. Further studies are needed to confirm these results and introduce HYPO-RT in the clinical routine
-
+
P2.04 - Poster Session with Presenters Present (ID 466)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.04-021 - Role of Adjuvant Radiotherapy and Prognostic Factor Analysis in Thymic Malignancies: A Retrospective Analysis of 129 Consecutive Patients (ID 5004)
14:30 - 14:30 | Author(s): A. Bruni
- Abstract
Background:
To evaluate the impact of histological subtypes, stage and therapeutic approaches on outcomes of a retrospective consecutive series of patients (pts) treated in 2 different Radiation Oncology Italian Centers
Methods:
One-hundred twenty nine pts were treated between 1982 and 2012.Sixty-six pts were male,63female;mean age was 58 years.The series was reclassified according to WHO 2004 staging:42 pts had epithelial/ mixed thymoma(type A/AB),72pts had cortical/medullary/atypical thymoma(B1/B2/B3) and 15 thymic carcinoma(type C).All pts were also staged using Masaoka classification(MKc) resulting in 43pts in stage I,30 stage IIA,13 stage IIB,24 stage III and 19 stage IVA.Radical surgery(thymectomy +/- mediastinal nodes sampling)was performed in all pts,30 of whom had positive margins,while 80 were also submitted to adjuvant thoracic RT(ART)due to their final pathological stage and/or surgical margins status. All pts were evaluated for clinical outcomes(overall survival-OS,progression free survival-PFS and local control-LC) and secondary malignancies incidence.
Results:
After a median follow up of 9.6 years,at time of analysis 103 pts were alive with a 5- and 10 year OS of 90.1%(SE±2,7)and 81.7(SE±3.7) respectively and a PFS of 84.8(SE±3.2) and 77.3(SE±4.0). Finally,5- and 10-year LC were respectively 94,1% (SE±2,2) and 89.2%(SE±3.2).In terms of OS, MKc advanced stage was found as a negative prognostic factors(p<0.0001) such as Performance Status (PS) with a p<0.0001, Tstage (p< 0,0001), aggressive histology (p=0.0001) and surgical positive margins (p< 0,0001) at univariate analysis. Regarding PFS,advanced MK stage,T stage, positive surgical margins and aggressive histology were confirmed as negative prognostic factor (p< 0,0001, p<0,0001, p<0,01, p<0,0001). Using Cox regression analysis ART seems to have a protective effect if stratified by MKc clinical stage (p< 0,03) just in terms of OS.Concerning local recurrence, a significant difference was found by T stage(p<0,001), surgical margins (p<0,03) and WHO classification(p=0.0001). At multivariate analysis PS, Surgical Margins and histology were statistically significant (p<0.0001, p<0.002 and p<0,001 respectively) with a negative impact on OS for PS>1, positive margins and thymic carcinoma differentiation. At the same analysis only thymic carcinoma differentiation influenced PFS when compared with PS, T and MKc stage, surgical margins and ART. During follow up secondary/methacronous neoplasms were diagnosed in 29 pts (22.5%)
Conclusion:
PS, surgical margins and WHO classification seems to be the most important indicators for long term survival. ART showed positive impact in terms of OS in advanced MKc clinical stage (Stage II-III) pts.
-
+
P2.05 - Poster Session with Presenters Present (ID 463)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.05-019 - Stereotactic Body Radiotherapy (SBRT) for Central Lung Tumors: The Experience of Florence University-Careggi Hospital Radiotherapy (ID 6047)
14:30 - 14:30 | Author(s): A. Bruni
- Abstract
Background:
Stereotactic body radiotherapy (SBRT) for central lung tumors, defined as tumor within 2 cm or touching the zone of the proximal bronchial tree or tumors immediately adjacent to the mediastinal or pericardial pleura (Adebahr S. et al. BJR 2015) is debated because of toxicities to organs at risk. No evidences from phase III trial are available.
Methods:
From 2010 to 2015, 45 central lesions in 40 pts were treated with SBRT. 14 lesions were primary lung cancer (PLC), 31 were lymphoadenopathies (LAP). PLC were treated with volumetric arc Therapy (VMAT) in 9 cases and 5 with Cyberknife®. LAP were treated with VMAT in 12 cases, with IMRT (step and shoot) in 10 and with Cyberknife® in 9 cases. Prescribed doses varied between 18 and 60 Gy (1-8 fractions) with median BED of 65 Gy (37,5-105 Gy). We evaluated Overall Survival (OS), Progression Free Survival (PFS) and Disease Specific Survival (DSS) using Kaplan-Meier method and treatment related toxicities using CTCAE version 4.0.
Results:
Median age was 62 years (48-86), 26 male and 14 female. PS was 0 in 9 pts, 1 in 21, 2 in 10 pts. Histology was available in all series and consisted of primary NSCLC (32 adenocarcinoma, 12 squamous cell carcinomas, 1 neuroendocrine tumour). 41 PLC were less than 2 cm from proximal bronchial tree, 4 PLC were immediately adjacent to the mediastinal or pericardial pleura. Tumor diameter was 10 to 60 mm with a median of 31 mm. Median follow up was 14,5 months. OS and DSS were 86.5% at 1 year, 55.6% at 2 years, and 49,4% at 3 years. PFS was 48,6% at 1 year, 24,1% at 2 years, and 12% at 3 years. 35 pts showed no acute toxicity; in 5 pts we recorded grade 1-2 esophagitis, in 2 pts grade 2 cough, in 2 pts, grade 1 asthenia. Chronic toxicity was present in 2 pts as grade 2 esophagitis.
Conclusion:
SBRT is confirmed to be a safe and effective strategy for central lung tumors. The majority of patients in the first part of our series was treated with low doses compared to current doses. Nevertheless 23 patients had clinical benefit from the treatment without life-threatening toxicities. Further studies are needed to establish the efficacy and safety of SBRT in central lung lesions.
